Aridis Pharmaceuticals

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARDS and other ETFs, options, and stocks.

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201.

CEO

Vu L. Truong

CEOVu L. Truong

Employees

Employees34

Headquarters

Los Gatos, California

HeadquartersLos Gatos, California

Founded

2003

Founded2003

Employees

Employees34

ARDS Key Statistics

Market cap

13.86M

Market cap13.86M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

4.65M

Average volume4.65M

High today

—

High today—

Low today

—

Low today—

Open price

$0.6701

Open price$0.6701

Volume

5.33K

Volume5.33K

52 Week high

$2.94

52 Week high$2.94

52 Week low

$0.5722

52 Week low$0.5722

ARDS News

Yahoo Finance 7d

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia - Yahoo Finance

Aridis Pharmaceuticals, Inc. LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results f...

ARDS Earnings

-$1.94

-$1.29

-$0.65

$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 30, After Hours

ActualExpected Mar 30, After Hours